HUE040274T2 - Heteroarilamidok a proteinaggregáció inhibitoraiként - Google Patents

Heteroarilamidok a proteinaggregáció inhibitoraiként

Info

Publication number
HUE040274T2
HUE040274T2 HUE15705417A HUE15705417A HUE040274T2 HU E040274 T2 HUE040274 T2 HU E040274T2 HU E15705417 A HUE15705417 A HU E15705417A HU E15705417 A HUE15705417 A HU E15705417A HU E040274 T2 HUE040274 T2 HU E040274T2
Authority
HU
Hungary
Prior art keywords
heteroarylamides
inhibitors
protein aggregation
aggregation
protein
Prior art date
Application number
HUE15705417A
Other languages
English (en)
Hungarian (hu)
Inventor
Emily Stocking
Wolfgang Wrasidlo
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52484559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE040274(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of HUE040274T2 publication Critical patent/HUE040274T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE15705417A 2014-01-29 2015-01-28 Heteroarilamidok a proteinaggregáció inhibitoraiként HUE040274T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461933246P 2014-01-29 2014-01-29
US201462078895P 2014-11-12 2014-11-12

Publications (1)

Publication Number Publication Date
HUE040274T2 true HUE040274T2 (hu) 2019-03-28

Family

ID=52484559

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE15705417A HUE040274T2 (hu) 2014-01-29 2015-01-28 Heteroarilamidok a proteinaggregáció inhibitoraiként
HUE18156929A HUE050964T2 (hu) 2014-01-29 2015-01-28 Heteroaril amidok mint protein aggregáció inhibitorai

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE18156929A HUE050964T2 (hu) 2014-01-29 2015-01-28 Heteroaril amidok mint protein aggregáció inhibitorai

Country Status (38)

Country Link
US (3) US9738635B2 (https=)
EP (2) EP3348556B1 (https=)
JP (2) JP6619741B2 (https=)
KR (1) KR102383038B1 (https=)
CN (2) CN106132960B (https=)
AP (1) AP2016009347A0 (https=)
AU (1) AU2015211119B2 (https=)
BR (2) BR112016017344B1 (https=)
CA (1) CA2937967C (https=)
CL (1) CL2016001918A1 (https=)
CR (1) CR20160394A (https=)
CY (2) CY1120348T1 (https=)
DK (2) DK3099684T3 (https=)
EA (1) EA032374B1 (https=)
EC (1) ECSP16070327A (https=)
ES (2) ES2808978T3 (https=)
HK (1) HK1231470A1 (https=)
HR (2) HRP20180813T1 (https=)
HU (2) HUE040274T2 (https=)
IL (1) IL246987B (https=)
LT (2) LT3099684T (https=)
ME (1) ME03800B (https=)
MX (1) MX2016009896A (https=)
MY (1) MY187450A (https=)
NZ (1) NZ722487A (https=)
PE (1) PE20161393A1 (https=)
PH (1) PH12016501493B1 (https=)
PL (2) PL3348556T3 (https=)
PT (2) PT3099684T (https=)
RS (2) RS60547B1 (https=)
SA (1) SA516371579B1 (https=)
SG (1) SG11201606108RA (https=)
SI (2) SI3099684T1 (https=)
SM (2) SMT201800318T1 (https=)
TR (1) TR201809440T4 (https=)
UA (1) UA118209C2 (https=)
WO (1) WO2015116663A1 (https=)
ZA (1) ZA201605246B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA032374B1 (ru) 2014-01-29 2019-05-31 ЮСиБи БАЙОФАРМА СПРЛ Гетероарильные амиды в качестве ингибиторов агрегации белков
ES2885049T3 (es) 2015-07-29 2021-12-13 UCB Biopharma SRL Derivados de bis-heteroarilo como moduladores de la agregación de proteínas
CN107625767A (zh) * 2016-11-25 2018-01-26 刘淑兰 一种治疗慢性盆腔炎的药物
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
CN110167937B (zh) * 2017-01-26 2022-03-29 Ucb生物制药私人有限公司 作为蛋白质聚集调节剂的二环双-杂芳基衍生物
US10913735B2 (en) 2017-01-26 2021-02-09 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
WO2018138085A1 (en) 2017-01-26 2018-08-02 Ucb Biopharma Sprl Alkoxy bis-heteroaryl derivatives as modulators of protein aggregation
JP7283699B2 (ja) * 2017-05-12 2023-05-30 マックス－プランク－ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 黒色腫の治療または予防において使用するためのフェニル－ヘテロ環－フェニル誘導体
US11505528B2 (en) 2017-08-04 2022-11-22 Axial Therapeutics, Inc. Inhibitors of microbially induced amyloid
WO2019089640A1 (en) * 2017-10-31 2019-05-09 Loma Linda University Methods for treating traumatic brain injury
EP3841100A1 (en) 2018-08-20 2021-06-30 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
US20250074902A1 (en) 2021-12-27 2025-03-06 Shanghai Jingxin Biomedical Co., Ltd. Fused bicyclic heteroaryl amide compound as protein aggregation inhibitor
GB202213796D0 (en) * 2022-09-21 2022-11-02 Wista Lab Ltd Tau aggregation inhibitors
CN120265630A (zh) * 2022-11-02 2025-07-04 Ac免疫有限公司 用于诊断tdp-43蛋白质病的新化合物
WO2024184180A1 (en) 2023-03-06 2024-09-12 UCB Biopharma SRL Minzasolmin for use in the treatment of parkinson's disease
WO2024184179A1 (en) 2023-03-06 2024-09-12 UCB Biopharma SRL Minzasolmin for use in the treatment of parkinson's disease
CN121487929A (zh) * 2023-06-25 2026-02-06 上海京新生物医药有限公司 双环杂芳基酰胺化合物的晶型及盐、制备方法和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1463997A (en) * 1995-12-22 1997-07-17 Acea Pharmaceuticals, Inc. Subtype-selective nmda receptor ligands and the use thereof
BR0316680A (pt) * 2002-11-28 2005-10-18 Schering Ag Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos
CN101385722A (zh) * 2003-02-27 2009-03-18 乔安妮·麦克劳林 预防、治疗和诊断蛋白聚集疾病的方法
DK1697371T3 (da) * 2003-12-19 2007-09-17 Bristol Myers Squibb Co Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
TW200528455A (en) * 2003-12-19 2005-09-01 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
KR20070018824A (ko) * 2003-12-19 2007-02-14 브리스톨-마이어스 스큅 컴퍼니 카나비노이드 수용체 조절제인 아자비사이클릭헤테로사이클
BR122020017756B1 (pt) * 2004-08-26 2022-02-15 Pfizer Inc Uso de compostos de aminoeteroarila enantiomericamente puros na preparação de um medicamento para o tratamento de crescimento celular anormal em um mamífero
WO2006032322A1 (en) * 2004-09-20 2006-03-30 4Sc Ag NOVEL HETEROCYCLIC NF-κB INHIBITORS
SE0403119D0 (sv) * 2004-12-21 2004-12-21 Astrazeneca Ab Therapeutic agents
JP2009505948A (ja) * 2005-07-11 2009-02-12 デブジェン エヌブイ キナーゼ阻害剤としてのアミド誘導体
WO2007016979A2 (en) * 2005-07-29 2007-02-15 4Sc Ag NOVEL HETEROCYCLIC NF-κB INHIBITORS
EA200801838A1 (ru) * 2006-03-15 2009-02-27 4ЭсЦэ АГ НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-kB
CA2668744C (en) * 2006-11-17 2015-09-15 Queen's University At Kingston Compounds and methods for treating protein folding disorders
US8450481B2 (en) * 2007-06-14 2013-05-28 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
US8598356B2 (en) * 2008-11-25 2013-12-03 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
GB0910003D0 (en) * 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
JP2013508350A (ja) * 2009-10-20 2013-03-07 ファイザー・インク ガンマ−セクレターゼモジュレーターとしての新規なヘテロアリールイミダゾールおよびヘテロアリールトリアゾール
NZ600449A (en) * 2009-12-16 2014-10-31 Neuropore Therapies Inc Compound suitable for the treatment of synucleopathies
GB201021103D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
WO2013134371A1 (en) 2012-03-06 2013-09-12 Neuropore Therapies, Inc. Methods and compounds to be used in the treatment of neurodegenerative diseases
CA2867175A1 (en) 2012-03-28 2013-10-03 Neuropore Therapies, Inc. Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
ES2661394T3 (es) 2012-07-16 2018-03-28 Neuropore Therapies, Inc. Derivados de di- y tri-heteroarilo como inhibidores de la agregación de proteínas
EA032374B1 (ru) 2014-01-29 2019-05-31 ЮСиБи БАЙОФАРМА СПРЛ Гетероарильные амиды в качестве ингибиторов агрегации белков
ES2885049T3 (es) 2015-07-29 2021-12-13 UCB Biopharma SRL Derivados de bis-heteroarilo como moduladores de la agregación de proteínas
CN110167937B (zh) 2017-01-26 2022-03-29 Ucb生物制药私人有限公司 作为蛋白质聚集调节剂的二环双-杂芳基衍生物
US10913735B2 (en) 2017-01-26 2021-02-09 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation

Also Published As

Publication number Publication date
PE20161393A1 (es) 2017-01-08
US20180093979A1 (en) 2018-04-05
UA118209C2 (uk) 2018-12-10
AU2015211119A1 (en) 2016-08-11
BR122018001892B1 (pt) 2023-05-02
KR102383038B1 (ko) 2022-04-05
ME03800B (me) 2021-04-20
CA2937967A1 (en) 2015-08-06
MY187450A (en) 2021-09-22
CY1123374T1 (el) 2021-12-31
SG11201606108RA (en) 2016-08-30
HK1231470A1 (zh) 2017-12-22
WO2015116663A8 (en) 2016-09-15
BR112016017344A2 (pt) 2017-10-03
US20190308965A1 (en) 2019-10-10
EP3099684B8 (en) 2018-07-04
ECSP16070327A (es) 2018-05-31
SI3348556T1 (sl) 2020-10-30
PL3348556T3 (pl) 2020-11-02
SI3099684T1 (en) 2018-08-31
PT3099684T (pt) 2018-10-22
HRP20201107T8 (hr) 2020-12-11
SMT201800318T1 (it) 2018-07-17
BR112016017344B1 (pt) 2023-05-16
EA032374B1 (ru) 2019-05-31
AU2015211119B2 (en) 2019-05-30
CA2937967C (en) 2022-07-26
KR20160113287A (ko) 2016-09-28
TR201809440T4 (tr) 2018-07-23
PL3099684T3 (pl) 2018-09-28
US20160207912A1 (en) 2016-07-21
ES2808978T8 (es) 2021-03-22
HRP20201107T1 (hr) 2020-10-30
PH12016501493A1 (en) 2017-02-06
SMT202000376T1 (it) 2020-09-10
DK3099684T3 (en) 2018-07-16
DK3348556T3 (da) 2020-08-03
SA516371579B1 (ar) 2019-07-16
HUE050964T2 (hu) 2021-01-28
IL246987B (en) 2021-12-01
CN106132960A (zh) 2016-11-16
MX2016009896A (es) 2017-01-11
PT3348556T (pt) 2020-07-27
IL246987A0 (en) 2016-09-29
NZ722487A (en) 2022-04-29
US10358443B2 (en) 2019-07-23
US9738635B2 (en) 2017-08-22
EP3099684A1 (en) 2016-12-07
AU2015211119A8 (en) 2016-12-15
ZA201605246B (en) 2022-05-25
HRP20180813T1 (hr) 2018-07-27
JP2017505779A (ja) 2017-02-23
CN106132960B (zh) 2019-12-17
CY1120348T1 (el) 2019-07-10
LT3348556T (lt) 2020-08-10
AP2016009347A0 (en) 2016-07-31
ES2675301T3 (es) 2018-07-10
CN111039939A (zh) 2020-04-21
ES2808978T3 (es) 2021-03-02
RS60547B1 (sr) 2020-08-31
JP6619741B2 (ja) 2019-12-11
CR20160394A (es) 2016-11-01
CL2016001918A1 (es) 2017-01-13
JP6783900B2 (ja) 2020-11-11
PH12016501493B1 (en) 2017-02-06
CN111039939B (zh) 2023-09-19
RS57533B1 (sr) 2018-10-31
EA201691529A1 (ru) 2017-01-30
LT3099684T (lt) 2018-06-25
US11078196B2 (en) 2021-08-03
JP2019163321A (ja) 2019-09-26
EP3099684B1 (en) 2018-04-04
EP3348556B1 (en) 2020-04-29
WO2015116663A1 (en) 2015-08-06
EP3348556A1 (en) 2018-07-18

Similar Documents

Publication Publication Date Title
HUE040274T2 (hu) Heteroarilamidok a proteinaggregáció inhibitoraiként
HUE042335T2 (hu) ROR-gamma dihidropirrolopiridin inhibitorai
LT3137169T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
LT3303334T (lt) Tirozinkinazės inhibitoriai
HUE050564T2 (hu) Lizinspecifikus demetiláz-1 inhibitorai
DK3119772T3 (da) Heteroaryl syk-hæmmere
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
HUE058852T2 (hu) Lizinspecifikus demetiláz-1 inhibitorai
DK3191487T3 (da) Spirocykliske cathepsin-c-inhibitorer
BR112017000042A2 (pt) inibidores de desmetilase-1 lisina-específica
LT3237432T (lt) Baltymo gamyba
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3132009T3 (da) Fremgangsmåde
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
EP3494971C0 (en) ERK INHIBITOR SALTS
DK3099791T3 (da) Protein
LT3212237T (lt) Metotreksato vaistinė forma
MA41266A (fr) Cataplasme
HRP20181441T1 (hr) Inhibitori sintaze aldosterona
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3143018T3 (da) Carboxamidderivater
HRP20182029T1 (hr) Uti-fuzijski proteini
DK3099793T3 (da) Protein
LT3097076T (lt) Nauji cip-eikozanoidų dariniai
TH1501006052A (th) สารยับยั้ง bacei